Jan-Erik Nyström

Jan-Erik Nyström

Born 1953

Member of the board since  2019

Jan-Erik has more than 25 years of experience from leading positions in industrial pharmaceutical research including 21 years from AstraZeneca in roles such as Head of pharmaceutical chemistry and Research Director for the Swedish research organization within CNS and Pain Control.
Jan-Erik has extensive experience from various management teams and boards. Since 2012, Jan-Erik has several engagements for the Life Science sector through his company Alveiro LifeScience. Areas of expertise are early drug development, drug chemistry and intellectual property rights. Jan-Erik has solid experience from pharmacology, CMC, toxicology, business development, licensing and clinical development.


M.Sc in Chemistry, Doctor of Technology and lecturer in organic chemistry, Royal Institute of Technology (KTH)

Other assignments

CEO, Alveiro AB
Chairman of the board, TIRmed Pharma.
Member of the board of ”Stiftelsen Gunnar och Elsa Jäderlunds Minne”

Number of shares (As of  september 20th, 2021)

15 052

Jan-Erik is independent in relation to the Company and its senior executives as well as independent
in relation to major shareholders.